Open AccessMucosal vaccination with a recombinant OprF‐I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule
Author(s) -
Göcke Kerstin,
Baumann Ulrich,
Hagemann Hartmut,
Gabelsberger Josef,
Hahn Heinz,
Freihorst Joachim,
Specht Bernd Ulrich
Publication year - 2003
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00094-4
Subject(s) - booster (rocketry) , vaccination , vaccination schedule , recombinant dna , schedule , immunology , pseudomonas aeruginosa , booster dose , microbiology and biotechnology , biology , virology , medicine , immunization , immune system , bacteria , computer science , physics , biochemistry , genetics , astronomy , gene , operating system
We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF‐I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF‐I‐specific serum antibodies of IgG isotype, with a mean±S.E.M. of 32.6±7.8×10 7 enzyme‐linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6±2.1×10 7 EU ( P =0.05 ). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF‐I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long‐term immunogenicity and induction of antibodies on the respiratory airway surface are warranted.